Last reviewed · How we verify
Ado-trastuzumab emtamsine
Ado-trastuzumab emtansine is a HER2-targeting antibody-drug conjugate that delivers a cytotoxic agent to HER2-positive cancer cells.
Ado-trastuzumab emtansine is a HER2-targeting antibody-drug conjugate that delivers a cytotoxic agent to HER2-positive cancer cells. Used for Adjuvant treatment of HER2-positive breast cancer.
At a glance
| Generic name | Ado-trastuzumab emtamsine |
|---|---|
| Also known as | Kadcyla |
| Sponsor | Hoffmann-La Roche |
| Drug class | HER2-targeting antibody-drug conjugate |
| Target | HER2 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
It works by binding to the HER2 receptor on the surface of cancer cells, which then internalizes the conjugate and releases the cytotoxic agent, causing cell death. This targeted approach aims to minimize harm to healthy cells.
Approved indications
- Adjuvant treatment of HER2-positive breast cancer
Common side effects
- Fatigue
- Nausea
- Diarrhea
- Vomiting
- Hair loss
- Neutropenia
- Thrombocytopenia
- Anemia
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ado-trastuzumab emtamsine CI brief — competitive landscape report
- Ado-trastuzumab emtamsine updates RSS · CI watch RSS
- Hoffmann-La Roche portfolio CI